Literature DB >> 1421644

Cephalexin-induced Stevens-Johnson syndrome.

K M Murray1, M S Camp.   

Abstract

OBJECTIVE: To report a case of cephalexin-induced Stevens-Johnson syndrome (SJS), a devastating adverse drug reaction that involves the entire skin surface and mucosal areas of the body. DATA SOURCES: MEDLINE search (key terms cephalosporins, Stevens-Johnson syndrome, erythema multiforme, and systemic lupus erythematosus) and references identified from bibliographies of pertinent articles. DATA SYNTHESIS: Clinical presentation and manifestations of SJS include the skin, eyes, gastrointestinal tract, and pulmonary system. Infectious complications are the leading cause of mortality. Early intervention is important to prevent progression of SJS. The case described is consistent with the features of this syndrome. The patient presented with fever, arthralgias, and malaise. Skin lesions included a diffuse violet macular rash with erythema and multiple bullous lesions on her neck and abdomen. The skin biopsy was consistent with SJS. Multiple mucocutaneous ulcers were found in her mouth, but no evidence of lower gastrointestinal tract involvement was documented. She remained relatively free of pulmonary complaints except for the presenting bronchitis.
CONCLUSIONS: Cephalexin should be added to the list of agents to consider as iatrogenic causes of SJS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1421644     DOI: 10.1177/106002809202601006

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  2 in total

1.  Fatal case of cephalexin-induced toxic epidermal necrolysis.

Authors:  Matthew J Hafermann; Gerard R Barber; Stephen C Dreskin; Gordon K Lindberg
Journal:  SAGE Open Med Case Rep       Date:  2014-04-17

2.  Case report: Alpelisib-induced Stevens-Johnson syndrome.

Authors:  Christine Jane Kurian; Akshay Desai; William Rafferty; Ahmed Kamel Abou Hussein
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.